These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 34762160)

  • 21. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.
    Bayliss J; Mukherjee P; Lu C; Jain SU; Chung C; Martinez D; Sabari B; Margol AS; Panwalkar P; Parolia A; Pekmezci M; McEachin RC; Cieslik M; Tamrazi B; Garcia BA; La Rocca G; Santi M; Lewis PW; Hawkins C; Melnick A; David Allis C; Thompson CB; Chinnaiyan AM; Judkins AR; Venneti S
    Sci Transl Med; 2016 Nov; 8(366):366ra161. PubMed ID: 27881822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience.
    Tanrıkulu B; Danyeli AE; Özek MM
    Childs Nerv Syst; 2020 May; 36(5):941-949. PubMed ID: 32025869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. H3 K27M mutations are extremely rare in posterior fossa group A ependymoma.
    Ryall S; Guzman M; Elbabaa SK; Luu B; Mack SC; Zapotocky M; Taylor MD; Hawkins C; Ramaswamy V
    Childs Nerv Syst; 2017 Jul; 33(7):1047-1051. PubMed ID: 28623522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
    Nobusawa S; Hirato J; Yokoo H
    Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
    Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
    Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.
    Mack SC; Pajtler KW; Chavez L; Okonechnikov K; Bertrand KC; Wang X; Erkek S; Federation A; Song A; Lee C; Wang X; McDonald L; Morrow JJ; Saiakhova A; Sin-Chan P; Wu Q; Michaelraj KA; Miller TE; Hubert CG; Ryzhova M; Garzia L; Donovan L; Dombrowski S; Factor DC; Luu B; Valentim CLL; Gimple RC; Morton A; Kim L; Prager BC; Lee JJY; Wu X; Zuccaro J; Thompson Y; Holgado BL; Reimand J; Ke SQ; Tropper A; Lai S; Vijayarajah S; Doan S; Mahadev V; Miñan AF; Gröbner SN; Lienhard M; Zapatka M; Huang Z; Aldape KD; Carcaboso AM; Houghton PJ; Keir ST; Milde T; Witt H; Li Y; Li CJ; Bian XW; Jones DTW; Scott I; Singh SK; Huang A; Dirks PB; Bouffet E; Bradner JE; Ramaswamy V; Jabado N; Rutka JT; Northcott PA; Lupien M; Lichter P; Korshunov A; Scacheri PC; Pfister SM; Kool M; Taylor MD; Rich JN
    Nature; 2018 Jan; 553(7686):101-105. PubMed ID: 29258295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TULIPs decorate the three-dimensional genome of PFA ependymoma.
    Johnston MJ; Lee JJY; Hu B; Nikolic A; Hasheminasabgorji E; Baguette A; Paik S; Chen H; Kumar S; Chen CCL; Jessa S; Balin P; Fong V; Zwaig M; Michealraj KA; Chen X; Zhang Y; Varadharajan S; Billon P; Juretic N; Daniels C; Rao AN; Giannini C; Thompson EM; Garami M; Hauser P; Pocza T; Ra YS; Cho BK; Kim SK; Wang KC; Lee JY; Grajkowska W; Perek-Polnik M; Agnihotri S; Mack S; Ellezam B; Weil A; Rich J; Bourque G; Chan JA; Yong VW; Lupien M; Ragoussis J; Kleinman C; Majewski J; Blanchette M; Jabado N; Taylor MD; Gallo M
    Cell; 2024 Sep; 187(18):4926-4945.e22. PubMed ID: 38986619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.
    Ramaswamy V; Hielscher T; Mack SC; Lassaletta A; Lin T; Pajtler KW; Jones DT; Luu B; Cavalli FM; Aldape K; Remke M; Mynarek M; Rutkowski S; Gururangan S; McLendon RE; Lipp ES; Dunham C; Hukin J; Eisenstat DD; Fulton D; van Landeghem FK; Santi M; van Veelen ML; Van Meir EG; Osuka S; Fan X; Muraszko KM; Tirapelli DP; Oba-Shinjo SM; Marie SK; Carlotti CG; Lee JY; Rao AA; Giannini C; Faria CC; Nunes S; Mora J; Hamilton RL; Hauser P; Jabado N; Petrecca K; Jung S; Massimi L; Zollo M; Cinalli G; Bognár L; Klekner A; Hortobágyi T; Leary S; Ermoian RP; Olson JM; Leonard JR; Gardner C; Grajkowska WA; Chambless LB; Cain J; Eberhart CG; Ahsan S; Massimino M; Giangaspero F; Buttarelli FR; Packer RJ; Emery L; Yong WH; Soto H; Liau LM; Everson R; Grossbach A; Shalaby T; Grotzer M; Karajannis MA; Zagzag D; Wheeler H; von Hoff K; Alonso MM; Tuñon T; Schüller U; Zitterbart K; Sterba J; Chan JA; Guzman M; Elbabaa SK; Colman H; Dhall G; Fisher PG; Fouladi M; Gajjar A; Goldman S; Hwang E; Kool M; Ladha H; Vera-Bolanos E; Wani K; Lieberman F; Mikkelsen T; Omuro AM; Pollack IF; Prados M; Robins HI; Soffietti R; Wu J; Metellus P; Tabori U; Bartels U; Bouffet E; Hawkins CE; Rutka JT; Dirks P; Pfister SM; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Ellison DW; Taylor MD
    J Clin Oncol; 2016 Jul; 34(21):2468-77. PubMed ID: 27269943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EZHIP's role in diffuse midline glioma: echoes of oncohistones?
    Cassim A; Dun MD; Gallego-Ortega D; Valdes-Mora F
    Trends Cancer; 2024 Dec; 10(12):1095-1105. PubMed ID: 39343635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYCN amplification drives an aggressive form of spinal ependymoma.
    Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
    Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
    Godfraind C; Kaczmarska JM; Kocak M; Dalton J; Wright KD; Sanford RA; Boop FA; Gajjar A; Merchant TE; Ellison DW
    Acta Neuropathol; 2012 Aug; 124(2):247-57. PubMed ID: 22526017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
    Shu C; Wang Q; Yan X; Wang J
    Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
    Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
    PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Molecular Subgroups on Prognosis and Survival Outcomes in Posterior Fossa Ependymomas: A Retrospective Study of 412 Cases.
    Wang B; Yan M; Han B; Liu X; Liu P
    Neurosurgery; 2024 Sep; 95(3):651-659. PubMed ID: 38529997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome.
    Jünger ST; Andreiuolo F; Mynarek M; Dörner E; Zur Mühlen A; Rutkowski S; von Bueren AO; Pietsch T
    Childs Nerv Syst; 2020 Nov; 36(11):2693-2700. PubMed ID: 32474813
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Whitehouse JP; Hii H; Mayoh C; Wong M; Ajuyah P; Barahona P; Cui L; Dholaria H; White CL; Buntine MK; Byrne J; Rodrigues da Silva K; Howlett M; Girard EJ; Tsoli M; Ziegler DS; Dyke JM; Lee S; Ekert PG; Cowley MJ; Gottardo NG; Endersby R
    Front Oncol; 2023; 13():1123492. PubMed ID: 36937401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
    Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
    Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
    Han J; Yu M; Bai Y; Yu J; Jin F; Li C; Zeng R; Peng J; Li A; Song X; Li H; Wu D; Li L
    Cancer Cell; 2020 Dec; 38(6):844-856.e7. PubMed ID: 33186520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of copy number variants in the classification of intracranial ependymoma.
    Evenson M; Cai C; Hucthagowder V; McNulty S; Neidich J; Kulkarni S; Dahiya S
    Cancer Genet; 2020 Jan; 240():66-72. PubMed ID: 31794935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.